Pharmacological Provocation Testing
Definition
Pharmacological provocation testing uses controlled drug administration to unmask latent arrhythmia syndromes and ECG patterns in patients with suspected arrhythmic conditions that cannot be confirmed by resting ECG or standard workup. Tests include sodium channel blocker (SCB) testing for Brugada syndrome, epinephrine/isoproterenol for CPVT/ARVC, adenosine for SVT/WPW, and acetylcholine/ergonovine for coronary artery spasm.
Key Concepts
General Principles
- Provocation testing offers a controlled environment to diagnose causes of SCD, cardiac arrest, arrhythmias, symptoms, or ECG abnormalities when baseline testing is non-diagnostic (sources/pharmacological-provocation-europace-2025 — high)
- All provocation tests must be performed in-hospital; minimum requirements include 12-lead ECG, vital signs monitoring, defibrillator, advanced life support personnel, and resuscitation medications (sources/pharmacological-provocation-europace-2025 — high)
- Evaluation of contraindications and patient counselling (pros/cons, implications of positive/negative result) are required before every test (sources/pharmacological-provocation-europace-2025 — high)
Sodium Channel Blocker (SCB) Testing for Brugada Syndrome
Agents
| Agent | Class | Half-life | Max dose | Notes |
|---|---|---|---|---|
| Ajmaline | 1A | ~5 min | 1 mg/kg (max 100 mg) | Preferred — shortest t½, most potent |
| Flecainide | 1C | 13–16 h | 2 mg/kg (max 150 mg) | Europe/USA alternative |
| Pilsicainide | 1C | 3–6 h | 1 mg/kg | Japan |
| Procainamide | 1A | 3–5 h | 15–18 mg/kg or 1000 mg | Least potent; North America |
(sources/pharmacological-provocation-europace-2025 — high)
False-Positive Rates — Specificity Problem
- ARVC patients: 16% type 1 pattern with ajmaline
- Myotonic dystrophy: 18%
- AVNRT patients: 27%
- Healthy Caucasian controls: 3–4.5%
- These false-positive rates mean a positive SCB test is not sufficient for definite BrS diagnosis in isolation; clinical, family history, and genetic evidence are required per Shanghai consensus (sources/pharmacological-provocation-europace-2025 — high)
Sensitivity Comparison
- Ajmaline vs procainamide in same mixed cohort: 26% vs 4% type 1 induction (P<0.001; Cheung et al.)
- Ajmaline vs flecainide in obligate BrS carriers: 100% vs 77% sensitivity (Therasse et al.)
- Only 68% of patients with prior ajmaline-induced type 1 reproduced with flecainide (Wolpert et al.) (sources/pharmacological-provocation-europace-2025 — high)
Stopping Criteria
Any of: (1) maximum dose reached; (2) type 1 Brugada pattern achieved; (3) QRS widening ≥30% from baseline; (4) VT/VF beyond isolated PVCs; (5) profound bradycardia or sinus arrest; (6) second or third-degree AV block; (7) allergic reaction (sources/pharmacological-provocation-europace-2025 — high)
Interpretation
- Positive = type 1 Brugada ECG pattern: J-point ≥0.2 mV with coved ST elevation and T-wave inversion in ≥1 right precordial lead (V1/V2, standard or high precordial position)
- J-point timing best identified in a limb lead; measure vertically from isoelectric line (PQ and TP segments) to J-point
- At least 2 beats must fulfil criteria; coved ST must descend continuously without concavity into negative T wave (sources/pharmacological-provocation-europace-2025 — high)
Clinical Scenarios — When to Test (>90% agreement)
- Unexplained VF/polymorphic VT after comprehensive evaluation excluding alternative causes
- First-degree relative of definite SCN5A-negative BrS patient
- Type 2/3 Brugada ECG pattern + cardiac/suspected cardiac syncope
- SADS relative when circumstances of death suggestive of BrS (sleep, fever, suspicious ECG in decedent)
- SCN5A variant of uncertain significance + symptoms/family history (segregation analysis) (sources/pharmacological-provocation-europace-2025 — high)
When NOT to Test (>90% agreement)
- Documented type 1 Brugada pattern already present (except phenocopy or ablation substrate mapping)
- Asymptomatic type 2/3 pattern with no supporting clinical, family, or genetic features
- SCN5A P/LP variant carriers — except in expert centres for specific indications (VUS assessment, complex phenotype)
- Active fever (sources/pharmacological-provocation-europace-2025 — high)
SCN5A-Specific Guidance
- Patients with SCN5A P/LP variants are at increased risk of ventricular arrhythmias during SCB testing (ventricular tachyarrhythmia risk)
- Routine diagnostic SCB testing in SCN5A P/LP carriers is generally not recommended; SCN5A positivity alone is not an indication for SCB testing (sources/pharmacological-provocation-europace-2025 — high)
Polygenic Context
- SCN5A P/LP variants identified in only ~20% of BrS cases; common SNPs (polygenic risk score) associate with ajmaline positivity independent of SCN5A status
- Genotype-negative relatives in SCN5A families may have positive SCB tests — higher polygenic risk score burden explains the finding
- Family members testing positive may carry polygenic susceptibility, not monogenic BrS — clinical implications are uncertain (sources/pharmacological-provocation-europace-2025 — high)
Epinephrine Testing
CPVT
- Epinephrine challenge is appropriate only when exercise stress test is not feasible (Class IIb ESC 2022)
- Positive criteria: >10 PVCs/min, 3 consecutive PVCs, recurrent couplets, sustained bigeminal rhythm, bidirectional VT; bidirectional VT is most specific for RYR2 P/LP variant
- Protocols: Mayo (progressive 0.025 → 0.20 µg/kg/min) or Shimizu (bolus 0.10 µg/kg then 0.10 µg/kg/min × 5 min) (sources/pharmacological-provocation-europace-2025 — high)
LQTS
- Epinephrine testing not recommended for LQTS by ESC 2022 or this consensus — high false-positive rate (up to 20% of controls), poor inter/intra-observer reproducibility; exercise test supersedes (sources/pharmacological-provocation-europace-2025 — high)
ARVC (Isoproterenol)
- High-dose isoproterenol infusion (45 µg/min × 3 min) has been used to improve early ARVC identification
- Positive = polymorphic PVCs (>3 morphologies) + ≥1 couplet, or sustained/non-sustained LBBB-morphology VT not typical for RVOT-VT
- Uncertain whether this test adds substantially beyond 2010 Task Force Criteria; not yet incorporated into standard guidelines (sources/pharmacological-provocation-europace-2025 — high)
Adenosine Testing
- Mechanism: AV node blockade via A1 receptor (Gi-coupled) → negative chronotropy and dromotropy; rapid onset, short duration, dose-dependent
- Indications: (1) Haemodynamically stable, regular wide QRS tachycardia — differential diagnosis of VT vs SVT with aberrancy; (2) Sinus rhythm with documented SVT or minimally pre-excited ECG — to unmask accessory pathway/WPW
- Interpretation: AV block terminating narrow or wide QRS tachycardia → re-entrant mechanism involving AV node; transient AV block in sinus rhythm revealing pre-excitation → WPW
- Absolute contraindication: AF in WPW or irregular wide QRS tachycardia (can cause VF via anterograde rapid accessory pathway conduction)
- Also contraindicated in: haemodynamic instability, LQTS with QT prolongation, severe AS/LVOTO, severe bronchospasm
- Max dose: up to 24 mg bolus; 12 mg superior to 6 mg (91% vs 62% SVT termination) (sources/pharmacological-provocation-europace-2025 — high)
Coronary Artery Spasm Testing (Acetylcholine/Ergonovine)
- Indication: Cardiac arrest survivor with clinical suspicion of CAS after all other tests are normal
- Technique: Intracoronary acetylcholine infusion (escalating: 2 → 20 → 50 µg; up to 100 µg for non-dominant left coronary artery; max 50 µg for right coronary artery/dominant left); ergonovine is alternative (more common in Asia)
- COVADIS diagnostic criteria for epicardial CAS: Reproduction of chest pain AND ischaemic ECG changes AND ≥90% epicardial vasoconstriction with flow limitation
- Safety profile: 0% mortality in recent series; <4% AF, <2% VT/VF, 0.1% SCA during procedure; events more common with right coronary testing
- Contraindications: Haemodynamic instability, early AMI, AV block, NYHA III/IV HF/cardiogenic shock, left main >50%, severe three-vessel CAD
- Ergonovine-specific contraindications: Pregnancy, severe hypertension, severe LV dysfunction, severe AS, high-grade left main stenosis
- If CAS confirmed: calcium channel blockers cornerstone; β-blockers are contraindicated (sources/pharmacological-provocation-europace-2025 — high)
Contradictions / Open Questions
- No gold standard for SCB testing validation: Without a definitive gold standard for BrS diagnosis, the true sensitivity and specificity of each SCB agent cannot be rigorously calculated; yield estimates vary widely across cohorts, indication, and agent (sources/pharmacological-provocation-europace-2025 — high)
- Routine CAS testing in all unexplained cardiac arrest survivors: Whether all unexplained cardiac arrest survivors (not just those with CAS-suggestive features) benefit from systematic CAS testing remains uncertain; 30–75% positivity rate suggests high prevalence but causal attribution is difficult (sources/pharmacological-provocation-europace-2025 — high)
- Isoproterenol in ARVC: Utility over 2010 Task Force Criteria is unclear; no formal recommendation for or against in ARVC guidelines; distinction from RVOT-VT may require larger data (sources/pharmacological-provocation-europace-2025 — high)
- Asymptomatic genotype-negative relatives in SCN5A families: Whether SCB testing is appropriate in these relatives is uncertain (>70% agree on uncertainty) — positive results may reflect polygenic susceptibility and the clinical implications are unclear (sources/pharmacological-provocation-europace-2025 — high)
- AI algorithms may reduce need for provocation testing: Novel AI-ECG algorithms may predict test outcome or select higher-probability patients, potentially rendering provocation unnecessary in some individuals in the future (sources/pharmacological-provocation-europace-2025 — high)
Connections
- Related to entities/Brugada-Syndrome — primary clinical application of SCB testing
- Related to entities/CPVT — epinephrine testing when EST not feasible
- Related to entities/ARVC — isoproterenol testing; false-positive SCB rate
- Related to entities/Long-QT-Syndrome — epinephrine testing no longer recommended
- Related to concepts/Shanghai-Score-System — drug-induced type 1 non-diagnostic in isolation
- Related to concepts/Coronary-Vasospasm — acetylcholine/ergonovine protocol and COVADIS criteria
- Related to entities/SCN5A — carriers generally not tested with SCB
- Related to concepts/Sudden-Cardiac-Death — provocation testing for SCA survivors